CJC-1295 DAC

Quickstart highlights

Dosing & reconstitution guide

Standard protocol (2 mL = 1 mg/mL)

A 2 mg vial dissolved in 2 mL bacteriostatic water gives a concentration of 1 mg/mL. Calculate your own dilution →

Reconstitution steps

1. Let the vial reach room temperature and wash your hands.
2. Disinfect both rubber stoppers with an alcohol swab.
3. Draw up 2 mL of bacteriostatic water.
4. Inject the water slowly down the glass wall, not directly onto the powder.
5. Swirl gently until clear — never shake.
6. Label the vial with date and concentration and refrigerate.

Supplies needed

• CJC-1295 DAC vial (2 mg)
• Bacteriostatic water
• Mixing syringe (1–3 mL) and U-100 insulin syringes
• Alcohol swabs and sharps container

Protocol overview

Dosing protocol in research

Values as described in literature and research protocols; not dosing advice.

Storage instructions

• Lyophilised (powder): cool, dry and dark; long-term at −20 °C.
• After reconstitution: refrigerator at 2–8 °C, use within ~4 weeks.
• Avoid repeated freezing and thawing.

Important notes

How this works

CJC-1295 with DAC is a synthetic variant of Growth Hormone Releasing Hormone (GHRH). The addition of the Drug Affinity Complex (DAC) allows the peptide to bind to albumin in the blood. Researchers study this compound for its ability to provide sustained elevations in growth hormone levels.

This peptide binds to GHRH receptors in the pituitary gland to stimulate growth hormone release. While natural GHRH degrades within minutes, the DAC modification extends the half-life to between 6 and 8 days. This leads to a dose-dependent increase in both growth hormone and IGF-1, the latter being primarily produced in the liver. The JAK/STAT signaling pathway is central to the subsequent metabolic effects. Despite the constant stimulation due to the long duration of action, the body's natural pulsatile growth hormone secretion is preserved.

Clinical studies in healthy adults have shown that a single injection can elevate growth hormone and IGF-1 levels for up to two weeks. Research often focuses on effects on body composition, such as the ratio of lean mass to fat mass. The compound is not approved for human medical use by authorities such as the EMA or FDA. It is included on the WADA prohibited list. Many questions remain regarding long-term safety and the impact on natural hormonal balance over several years.

Potential benefits & side effects

Effects described in research

• Sustained IGF-1 elevation (up to 2 weeks in studies)
• Fewer injections required

Common side effects

• Temporary water retention
• Tingling or numbness in the hands
• Injection-site redness
• Headache
• Flushing and dizziness

Reported side effects in literature include water retention, transient flushing, and headaches. Users sometimes report irritation or redness at the injection site. As large-scale long-term studies are lacking, the risks associated with chronic exposure have not been fully mapped.

Contraindications

• Pregnancy or breastfeeding
• Active or prior cancer
• Under 18 years of age
• Uncontrolled diabetes

Lifestyle factors

• Administration on an empty stomach (2 h after / 30 min before food) is most often described.
• Carbohydrates and fat around administration blunt the GH pulse.
• Adequate sleep supports natural nocturnal GH release.

Injection technique

• Choose a site with subcutaneous fat: abdomen (5 cm from the navel), thigh or back of upper arm.
• Disinfect, pinch a skin fold and insert at a 45–90° angle.
• Inject slowly, wait 5 seconds and withdraw.
• Rotate sites and use each needle once.

Recommended source

Quality varies widely between suppliers. Look for an independent HPLC/MS lab report per batch, purity ≥ 98% and clear storage and shipping conditions.

As a reference we use the CJC-1295 DAC from PeptideWinkel, which publishes lab reports per batch.

Frequently asked questions